Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes

Life Sciences

Volumn 78, Issue 24, 2006, Pages 2860-2866

  Kawabe, Kenji ^a   Yoshikawa, Yutaka ^a   Adachi, Yusuke ^a   Sakurai, Hiromu ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Action mechanism; Adipocyte; Diabetes mellitus; Vanadyl complex

Indexed keywords

BIS(MALTOLATO)OXOVANADYL; BIS(PICOLINATO)OXOVANADYL; CILOSTAMIDE; CYTOCHALASIN B; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXY 2 NAPHTHALENYLMETHYL PHOSPHONIC ACID TRIS ACETOXYMETHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VANADYL DERIVATIVE; VANADYL SULFATE; WORTMANNIN;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ELECTRON SPIN RESONANCE; GLUCOSE METABOLISM; MALE; NONHUMAN; RAT;

ADIPOCYTES; ANIMALS; ANTIMETABOLITES; CELL SEPARATION; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HYPOGLYCEMIC AGENTS; PHOSPHODIESTERASE INHIBITORS; RATS; VANADATES;

ANIMALIA;

EID: 33646085332     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.11.008     Document Type: Article

References (62)

1. Adachi Y., and Sakurai H. Insulin-mimetic vanadyl(IV) complexes as evaluated by both glucose-uptake and inhibition of free fatty acids (FFA)-release in isolated rat adipocytes. Chemical & Pharmaceutical Bulletin 52 (2004) 428-433
2. Badmaev V., Prakash S., Majeed M., and Altern J. Vanadium: a review of its potential role in the fight against diabetes. Complementary Medicine 3 (1999) 273-291
3. Boyd D.W., and Kustin K. Vanadium: a versatile biochemical effector with an elusive biological function. Advances in Inorganic Biochemistry 6 (1984) 311-365
4. Brichard S.M., and Henquin J.C. The role of vanadium in the management of diabetes. Trends in Pharmacological Sciences 16 (1995) 265-270
5. Brichard S.M., Bailey C.J., and Henquin J.C. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes Review 39 (1999) 1326-1332
6. Cam M.C., Brownsey R.W., Rodrigues B., and McNeill J.H. Lack of in vivo effect of vanadium on GLUT4 translocation in white adipose tissue of streptozotocin-diabetic rats. Metabolism 50 (2001) 674-680
7. Chasteen N.D. In: Reuben J. (Ed). Biological Magnetic Resonance (1981), Plenum Press, New York 53-119
8. Cohen N., Halberstam P., Shlimovich P., Chang C.J., Shamoon H., and Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Journal of Clinical Investigation 95 (1995) 2501-2509
9. Crans D.C., and Tracey A.S. In: Crans D.C., and Tracey A.S. (Eds). Vanadium Compounds Chemistry, Biochemistry, and Therapeutic Applications (1998), Oxford University Press, New York 2-29
10. Cusi K., Cukier S., Defronzo R.A., Torres M., Puchulu F.M., and Redondo J.C. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 86 (2001) 1410-1417
11. 2+) stimulate glucose transport activity by post-insulin receptor kinase mechanism in rat adipocyte. Journal of Biological Chemistry 264 (1989) 16118-16122
12. Fantus I.G., Deragon G., Lai R., and Tang S. Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Molecular and Cellular Biochemistry 153 (1995) 103-112
13. Frevert E.U., and Kahn B.B. Differential effects of constitutively active PI3-k on glucose transport, glycogen synthase activity and DNA synthesis in 3T3-L1 adipocytes. Molecular and Cellular Biology 17 (1997) 190-198
14. Gherzi R., Caratti C., Andraghetti G., Bertolini S., Montemurro A., Sesti G., and Cordera R. Direct modulation of insulin receptor protein tyrosine kinase by vanadate and anti-insulin receptor monoclonal antibodies. Biochemical and Biophysical Research Communications 152 (1988) 1474-1480
15. Ghosh R., Mukherjee B., and Chatterjee M. A novel effect of selenium on streptozotocin-induced diabetic mice. Diabetes Research 25 (1994) 165-171
16. Goldfine A.B., Simonson D.C., Folli F., Patti M.E., and Kahn C.R. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 80 (1995) 3311-3320
17. Goldfine A.B., Patti M.E., Zuberi L., Goldstein B.J., LeBlanc R., Landaker E.J., Jiang Z.Y., Willsky G.R., and Kahn C.R. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 49 (2000) 400-410
18. Halberstam M., Cohen N., Shlimovich P., Rossetti L., and Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45 (1996) 659-666
19. Hidaka H., and Endo T. Selective inhibitors of three forms of cyclic nucreotide phosphodiesterase-basic and potential clinical applications. Advances in Cyclic Nucleotide and Protein Phosphorylation Research 16 (1984) 245-259
20. Horlington M., and Watson P.A. Inhibition of 3′, 5′-cyclic-AMP phosphodiesterase by some platelet aggregation inhibitors. Biochemical Pharmacology 19 (1970) 955-956
21. John A.C. Effects of cytochalasin and phallodin on actin. Molecular and Cellular Biology 105 (1987) 1473-1477
22. 2O)]. Chemistry Letters (1998) 9-10
23. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
24. Marzban L., and McNeill J.H. Insulin-like actions of vanadium: potential as therapeutic agent. Journal of Trace Elements in Experimental Medicine 16 (2003) 253-267
25. McNeill J.H., Yuen V.G., Hoveyda H.R., and Orvig C. Bis(maltolato)oxovanadium(IV) is a potent insulin mimetic. Journal of Medicinal Chemistry 35 (1992) 1489-1491
26. Mohammad A., Sharma V., and McNeill J.H. Vanadium increases GLUT4 in diabetic rat skeletal muscle. Molecular and Cellular Biochemistry 233 (2002) 139-143
27. Nakai M., Watanabe H., Fujisawa C., Kakegawa H., Satoh T., Takada J., Matsushita R., and Sakurai H. Mechanism on insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds. Biological & Pharmaceutical Bulletin 18 (1995) 719-725
28. Okada T., Sakuma L., Fukui Y., Hazeki O., and Ui M. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. Journal of Biological Chemistry 269 (1994) 3563-3567
29. Okada T., Kawano Y., Sakakibara T., Hazeki O., and Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Journal of Biological Chemistry 269 (1994) 3568-3573
30. Orvig C., Thompson K.H., Battell M., and McNeill J.H. Vanadium compounds as insulin mimics. Metal Ions in Biological Systems 31 (1995) 575-594
31. Papapetropoulos A., Fulton D., Lin M.I., Fontana J., McCabe T.J., Zoellner S., Garcia-Cardena G., Zhou Z., Gratton J.P., and Sessa W.C. Vanadate is a potent activator of endothelial nitric-oxide synthase: evidence for the role of the serine/threonine kinase Akt and the 90-kDa heat shock protein. Molecular Pharmacology 65 (2004) 407-415
32. Paquet M.R., Romanek R.J., and Sargeant R.J. Vanadate induces the recruitment of glut-4 glucose transporter to the plasma membrane of rat adipocyte. Molecular and Cellular Biochemistry 109 (1992) 149-155
33. Posner B.I., Faure R., and Burgess J.W. Peroxovanadium compounds. A new class of potent phosphotylosine phosphatase inhibitors which are insulin mimetics. Journal of Biological Chemistry 269 (1994) 4596-4604
34. Rodbell M. Metabolism of isolated fat cells: I. Effects of hormones on glucose metabolism and lipolysis. Journal of Biological Chemistry 239 (1964) 375-380
35. Rubenstein A.H., Levin N.W., and Elliott G.A. Hyperglycemia induced by manganese. Nature 194 (1962) 188-189
36. Sakurai H. A new concept: the use of vanadium complexes in the treatment of diabetes mellitus. Chemical Record 2 (2002) 237-248
37. Sakurai H., and Tsuji A. Antidiabetic action of vanadium complexes in animals: blood glucose normalizing effect, organ distribution of vanadium, and mechanism for insulin-mimetic action. In: Nriagu J.O. (Ed). Vanadium in the Environment: Part 2. Health Effects (1998), John Wiley & Sons 297-315
38. Sakurai H., and Yasui H. Structure-activity relationship of insulinomimetic vanadyl-picolinate complexes in view of their clinical use. Journal of Trace Elements in Experimental Medicine 16 (2003) 269-280
39. Sakurai H., Tsuchiya K., Nukatsuka M., Kawada J., Ishikawa S., Yoshida H., and Komatsu M. Insulin-mimetic action of vanadyl complexes. Journal of Clinical Biochemistry and Nutrition 8 (1990) 193-200
40. Sakurai H., Tsuchiya K., Nukatsuka M., Sofue M., and Kawada J. Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats. Journal of Endocrinology 126 (1990) 451-459
41. Sakurai H., Fujii K., Watanabe H., and Tamura H. Orally active and long-term acting insulin-mimetic vanadyl complex: Bis(picolinate)oxovanadium(IV). Biochemical and Biophysical Research Communications 214 (1995) 10950-11101
42. Sakurai H., Kojima Y., Yoshikawa Y., Kawabe K., and Yasui H. Antidiabetic vanadium(IV) and zinc(II) complexes. Coordination Chemistry Reviews 226 (2002) 187-198
43. Sakurai H., Yasui H., and Adachi Y. The therapeutic potential of insulin-mimetic vanadium complexes. Expert Opinion on Investigational Drugs 12 (2003) 1189-1203
44. Sakurai H., Fugono J., and Yasui H. Pharmacokinetic study and trial for preparation of enteric-coated capsule containing insulinomimetic vanadyl compounds: implications for clinical use. Mini Reviews in Medicinal Chemistry 4 (2004) 41-48
45. Saperstein R., Vicario P.P., Strout H.V., Brady E., Slater E.E., Greenlee W.J., Ondeyka D.L., Patchett A.A., and Hangauer D.G. Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells. Biochemistry 28 (1984) 5694-5701
46. y mice. Journal of Inorganic Biochemistry 88 (2002) 108-112
47. Schwarz K., and Mertz W. Chromium(III) and the glucose tolerance factor. Archives of Biochemistry and Biophysics 85 (1959) 292-295
48. Seale A.P., Jesus L.A., Kim A.Y., Choi Y.H., Lim H.B., Hwang C.S., and Kim Y.S. Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin enhancing vanadium(IV) and zinc(II) complexes. Biotechnology Letters 27 (2005) 221-225
49. Sekar N., Li J., and Shechter Y. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research. Critical Reviews in Biochemistry and Molecular Biology 31 (1996) 339-359
50. Shafrir E., Spielman S., Nachliel I., Khamaisi M., Bar-on H., and Ziv E. Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obese gerbil. Diabetes/Metabolism Research and Reviews 17 (2001) 55-66
51. Shechter Y., and Karlish S.J. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature 284 (1980) 556-558
52. Smith D.M., and Sale G.J. Evidence that a novel serine kinase catalyses phosphorylation of the insulin receptor in an insulin-dependent and tyrosine kinase-dependent manner. Biochemical Journal 256 (1988) 903-909
53. Swarup G., Cohen S., and Garbers D.L. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochemical and Biophysical Research Communications 107 (1982) 1104-1109
54. Tamura S., Brown T.A., Whipple Y., Fujita-Yamaguchi T., Dubler R.F., Cheng K., and Larner J. A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocyte. Journal of Biological Chemistry 259 (1984) 6650-6658
55. 2) coordination mode, and evaluation of its effect on uptake of d-glucose by Ehrlich ascites tumour cells. Journal of Pharmacy and Pharmacology 51 (1999) 119-124
56. Thompson K.H., and Orvig C. Design of vanadium compounds as insulin enhancing agents. Journal of the Chemical Society. Dalton Transactions 17 (2000) 2885-2892
57. Thompson K.H., McNeill J.H., and Orvig C. Vanadium compounds as insulin mimics. Chemical Reviews 99 (1999) 2561-2571
58. Tsiani E., Bogdanovic E., Sorisky A., Nagy L., and Fantus I.G. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independence of phosphatidylinositol 3-kinase and protein kinase C. Diabetes 47 (1998) 1676-1686
59. Ueki H., Okuhama R., Sera M., Inoue T., Tominaga N., and Morita T. Stimulatory affect of vanadate on 3′,5′-cyclic guanosine monophosphate-inhibited low Michaelis-Menten constant 3′5′-cyclic adenosine monophosphate phosphodiesterase activity in isolated rat fad pads. Endocrinology 131 (1992) 441-446
60. Watanabe T., Sato H., Kohara K., Takami R., Motoyashiki T., Morita T., and Ueki H. Orthovanadate stimulates cAMP phosphodiesterase 3 activity in isolated rat hepatocytes through mitogen-activated protein kinase activation dependent on cAMP-dependent protein kinase. Biological & Pharmaceutical Bulletin 27 (2004) 789-796
61. Wild S., Roglic G., Green A., Sicree R., and King H. Global burden of diabetes in the year 2000. Global Burden of Disease (2003), WHO, Geneva
62. Yoshikawa Y., Ueda E., Kojima Y., and Sakurai H. The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes. Life Sciences 75 (2004) 741-751